grant
Clinical treatment of advanced Merkel cell carcinoma
Organization NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY2025Adjuvant TherapyAssayB-Cell CLLB-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphogenous LeukemiaB-Cell Chronic Lymphoid LeukemiaB-Cell Lymphocytic LeukemiaB-Lymphocytic LeukemiaBioassayBiological AssayBiological MarkersBloodBlood Reticuloendothelial SystemCancer TreatmentChronic B-Lymphocytic LeukemiaChronic Lymphatic LeukemiaChronic Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaChronic Lymphogenous LeukemiaClinicalClinical ResearchClinical StudyClinical TreatmentClinical TrialsClinical Trials DesignCutaneous Neuroendocrine CarcinomaDevelopmentDiagnosisDiseaseDisorderEnrollmentEpidemiologic ResearchEpidemiologic StudiesEpidemiological StudiesEpidemiology ResearchGoalsHIV InfectionsHTLV-III InfectionsHTLV-III-LAV InfectionsHuman T-Lymphotropic Virus Type III InfectionsImmune mediated therapyImmune responseImmune systemImmunologically Directed TherapyImmunotherapyInstitutionMalignantMalignant - descriptorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMerkel Cell TumorMerkel cell cancerMerkel cell carcinomaNational Institutes of HealthNeuroendocrine Carcinoma of the SkinNeuroendocrine CellOperative ProceduresOperative Surgical ProceduresOrphan DiseasePD-L1 antibodyParticipantPatientsProtocolProtocols documentationRadiationRare DiseasesRare DisorderResearch SpecimenRisk FactorsSamplingSeminalSiteSkinSpecimenSurgicalSurgical InterventionsSurgical ProcedureTestingTrabecular Skin CarcinomaUnited States National Institutes of HealthaPD-L1aPD-L1 antibodiesadjuvant treatmentanti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-PD-(L)1anti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-cancer immunotherapyanti-cancer therapyanti-tumor immune responseantiPD-L1anticancer immunotherapybio-markersbiologic markerbiomarkercancer immunotherapycancer therapycancer-directed therapychronic lymphoid leukemiaclinical interventionclinical therapydevelopmentaldrug developmentdrug discoveryenrollepidemiologic investigationepidemiology studyhost responseimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimmunotherapy for cancerimmunotherapy of cancerinterestmicrobiomeopen labelopen label studyorphan disorderparticipant enrollmentpatient enrollmentphase 2 studyphase II studyresistance to therapyresistant to therapysurgerytherapeutic resistancetherapy resistanttooltreatment resistancetrial regimentrial treatmenttumorαPD-L1αPD-L1 antibodiesαPDL1
Description preview
Patients are enrolled in clinical trials designed to treat patients with advanced Merkel cell carcinoma or to provide adjuvant treatment to patients with earlier stage disease that has been treated with surgery or radiation. The NIH Clinical Research Center served as a study site in a seminal multi-institutional, open-label phase II study of EMD…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click